Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1370 68Ga-DOTATOC PET and Gene Expression Profile in Patients with Neuroendocrine Carcinomas

Introduction: Somatostatin receptor expression on both protein and gene expression levels were compared with in vivo 68Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Olsen I

Authors: Olsen I, Langer S, Federspiel B, Oxbøl J, Loft A,

Keywords: neuroendocrine carcinoma, gene expression, 68Ga-DOTATOC, IHC, SSTR2,

#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study

Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Heetfeld M, Rinke A, Borbath I, Crespo G, Olsen I,

Keywords: gastrointestinal cancer, neuroendocrine carcinoma, grade 3 NET, Ki-67, chemotherapy,

#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors

Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: olsen i

Authors: Olsen I, Borbath I, Heetfeld M, Walter T, Barriuso J,

Keywords: neuroendocrine carcinoma, Ki-67, immunohistochemistry, treatment,

#776 Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 85 Patients

Introduction: Appendiceal Goblet cell carcinoids (GCC) exhibit neuroendocrine and adenocarcinoma features.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Olsen I, Holt N, Langer S, Federspiel B, Hasselby J,

Keywords: prognosis,

#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas

Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,

Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!


The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.